364 related articles for article (PubMed ID: 24521710)
1. A global profile of gene promoter methylation in treatment-naïve urothelial cancer.
Ibragimova I; Dulaimi E; Slifker MJ; Chen DY; Uzzo RG; Cairns P
Epigenetics; 2014 May; 9(5):760-73. PubMed ID: 24521710
[TBL] [Abstract][Full Text] [Related]
2. Aberrant methylated key genes of methyl group metabolism within the molecular etiology of urothelial carcinogenesis.
Erichsen L; Ghanjati F; Beermann A; Poyet C; Hermanns T; Schulz WA; Seifert HH; Wild PJ; Buser L; Kröning A; Braunstein S; Anlauf M; Jankowiak S; Hassan M; Bendhack ML; Araúzo-Bravo MJ; Santourlidis S
Sci Rep; 2018 Feb; 8(1):3477. PubMed ID: 29472622
[TBL] [Abstract][Full Text] [Related]
3. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer.
Habuchi T; Takahashi T; Kakinuma H; Wang L; Tsuchiya N; Satoh S; Akao T; Sato K; Ogawa O; Knowles MA; Kato T
Oncogene; 2001 Jan; 20(4):531-7. PubMed ID: 11313984
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
6. Aberrant cell adhesiveness due to DNA hypermethylation of KLF11 in papillary urothelial carcinomas.
Tsumura K; Fujimoto M; Tian Y; Kawahara T; Fujimoto H; Maeshima AM; Nakagawa T; Kume H; Yoshida T; Kanai Y; Arai E
Exp Mol Pathol; 2024 Jun; 137():104908. PubMed ID: 38824688
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
8. Comparison of genome-wide DNA methylation in urothelial carcinomas of patients with and without arsenic exposure.
Yang TY; Hsu LI; Chiu AW; Pu YS; Wang SH; Liao YT; Wu MM; Wang YH; Chang CH; Lee TC; Chen CJ
Environ Res; 2014 Jan; 128():57-63. PubMed ID: 24268366
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
[TBL] [Abstract][Full Text] [Related]
10. Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival.
Jou YC; Tsai YS; Chen SY; Hsieh HY; Tsai HT; Tzai TS
Virchows Arch; 2016 Jun; 468(6):733-40. PubMed ID: 27003158
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
12. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Miller K; Schrader M
Int J Cancer; 2006 Sep; 119(6):1396-402. PubMed ID: 16642478
[TBL] [Abstract][Full Text] [Related]
13. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue.
Wolff EM; Chihara Y; Pan F; Weisenberger DJ; Siegmund KD; Sugano K; Kawashima K; Laird PW; Jones PA; Liang G
Cancer Res; 2010 Oct; 70(20):8169-78. PubMed ID: 20841482
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer.
Wu B; Cao X; Liang X; Zhang X; Zhang W; Sun G; Wang D
PLoS One; 2015; 10(1):e0117510. PubMed ID: 25629735
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation alterations in urothelial carcinoma.
Neuhausen A; Florl AR; Grimm MO; Schulz WA
Cancer Biol Ther; 2006 Aug; 5(8):993-1001. PubMed ID: 16775427
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma.
Wu MM; Li CF; Lin LF; Wang AS; Pu YS; Wang HH; Mar AC; Chen CJ; Lee TC
Oncotarget; 2017 Apr; 8(14):23787-23802. PubMed ID: 28423602
[TBL] [Abstract][Full Text] [Related]
18. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
Catto JW; Azzouzi AR; Rehman I; Feeley KM; Cross SS; Amira N; Fromont G; Sibony M; Cussenot O; Meuth M; Hamdy FC
J Clin Oncol; 2005 May; 23(13):2903-10. PubMed ID: 15753461
[TBL] [Abstract][Full Text] [Related]
19. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
20. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
Rose M; Schubert C; Dierichs L; Gaisa NT; Heer M; Heidenreich A; Knüchel R; Dahl E
Epigenetics; 2014 Dec; 9(12):1626-40. PubMed ID: 25625847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
